{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27","upperLimit":"73","value":"50"},{"groupId":"OG001","lowerLimit":"53","upperLimit":"100","value":"83"},{"comment":"Progression event (died without progression) at day 65, Sample size too small to estimate the rate and CI","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Day 92"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11","upperLimit":"55","value":"33"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"47","value":"17"},{"comment":"Progression event (died without progression) at day 65, Sample size too small to estimate the rate and CI","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Week 60"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Duration of time from start of treatment to time of objective disease progression or death, whichever comes first. AML progressive disease is defined in Appendix E (E.1.7.), and criteria for MDS/MPN is in Appendix F (F.1.4.).","dispersionType":"95% Confidence Interval","groups":[{"description":"1 mg/kg of Ipilimumab and 3x10\\^7 CD3+ cells/kg of CD25/Treg-depleted DLI will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.","id":"OG000","title":"Dose Level: 0"},{"description":"3 mg/kg of Ipilimumab and 3x10\\^7 CD3+ cells/kg of CD25/Treg-depleted DLI will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.","id":"OG001","title":"Dose Level: 1"},{"description":"10 mg/kg of Ipilimumab and 3x10\\^7 CD3+ cells/kg of CD25/Treg-depleted DLI will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.","id":"OG002","title":"Dose Level: 2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 92 and Week 60","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}